Department of Emergency Medicine, Harvard Affiliated Emergency Medicine Residency, Massachusetts General Hospital and Brigham and Women's Hospital, Boston, Massachusetts, USA.
Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Am J Addict. 2024 Nov;33(6):631-640. doi: 10.1111/ajad.13631. Epub 2024 Aug 5.
As overdose rates rise among non-White Americans, understanding barriers to substance use disorder (SUD) treatment access by race and ethnicity is important. This study explores self-reported barriers to SUD treatment by race and ethnicity in emergency department (ED) populations.
We conducted a secondary, exploratory analysis of a randomized trial of patients not seeking SUD treatment who endorsed active drug use at six academic EDs. Responses to the Barriers to Treatment Inventory were compared by race, ethnicity, and drug severity, using χ tests (N = 858), followed by adjusted logistic regression models.
Absence of a perceived drug problem (39% non-Hispanic Black, 38% Hispanic, 50% non-Hispanic White; p ≤ .001) was the most prevalent barrier to SUD treatment. Non-Hispanic Black participants were less likely to state that they could handle their drug use on their own (OR = 0.69, CI = 0.50-0.95), and were more likely to report disliking personal questions than non-Hispanic White participants (OR = 1.49, CI = 1.07-2.09). Non-Hispanic Black participants were less likely than Hispanic participants to agree that treatment availability (OR = 0.46, CI = 0.28-0.76) and family disapproval (OR = 0.38, CI = 0.16-0.91) were treatment barriers.
Screening and counseling may help address the barrier, common to all groups, that drug use was not seen as problematic. Expanding access to diverse treatment options may also address the range of barriers reported by our study population.
Our study is one of the first in the U.S. to examine both individual and structural barriers to accessing treatment and to examine the association with drug use severity by race/ethnicity.
随着非裔美国人群体中的药物过量率上升,了解种族和民族群体在获得物质使用障碍(SUD)治疗方面的障碍至关重要。本研究探讨了急诊科(ED)人群中自我报告的 SUD 治疗障碍与种族和民族的关系。
我们对六所学术 ED 中未寻求 SUD 治疗但报告正在使用毒品的患者进行了一项随机试验的二次、探索性分析。使用 χ 检验(N=858)比较了按种族、族裔和药物严重程度对治疗障碍清单的反应,然后使用调整后的逻辑回归模型进行分析。
39%的非西班牙裔黑人、38%的西班牙裔、50%的非西班牙裔白人认为不存在感知到的药物问题是 SUD 治疗的最常见障碍(p≤0.001)。非西班牙裔黑人参与者表示他们可以自己处理药物使用的可能性较小(OR=0.69,CI=0.50-0.95),并且比非西班牙裔白人参与者更有可能报告不喜欢个人问题(OR=1.49,CI=1.07-2.09)。非西班牙裔黑人参与者认为治疗可用性(OR=0.46,CI=0.28-0.76)和家庭反对(OR=0.38,CI=0.16-0.91)是治疗障碍的可能性小于西班牙裔参与者。
筛查和咨询可能有助于解决所有群体都认为药物使用没有问题的共同障碍。扩大对各种治疗选择的获取可能也有助于解决我们研究人群报告的一系列障碍。
我们的研究是美国首批研究种族/族裔与药物使用严重程度之间获得治疗障碍的个体和结构性障碍的研究之一。